Abstract
Irinotecan given until disease progression is an accepted standard treatment for advanced colorectal cancer (CRC) resistant to fluoropyrimidines. It is not known whether a predefined period of irinotecan treatment would result in similar duration of disease control. We performed a multicenter phase III trial to compare the two policies of defined-duration versus continuous irinotecan treatment.
Original language | English |
---|---|
Pages (from-to) | 3023-31 |
Number of pages | 9 |
Journal | Journal of Clinical Oncology |
Volume | 22 |
Issue number | 15 |
DOIs | |
Publication status | Published - 2004 |